Tuesday, October 27, 2026

HomeHealth NewsFDA approves Omvoh for moderately to severely active Crohn's disease

FDA approves Omvoh for moderately to severely active Crohn’s disease

- Advertisement -

The U.S. Food and Drug Administration has approved Eli Lilly’s Omvoh (mirikizumab-mrkz) for the treatment of moderately to severely active Crohn’s disease in adults.

Omvoh…

Click here to view the original article.

- Advertisment -
- Advertisement -

Recently Viewed